Formulation and Optimization of Polymeric Nanoparticles for Intranasal Delivery of Lorazepam Using Box-Behnken Design: In Vitro and In Vivo Evaluation

Table 4

Results of stability study conducted on the Lzp-PLGA-NPs for 90 days at 25 ± 2°C and 60 ± 5% RH.

Time (days)	𝑧-Average^a  ± S.D. (d·nm)	% Drug remaining
0	168 ± 0.11	100
30	171 ± 0.15	99.78 ± 0.08
60	179 ± 0.085	99.34 ± 0.5
90	186 ± 0.11	98.9 ± 0.3

aNot significant (P > 0.05).